Vivos Therapeutics (VVOS) Loans and Notes Receivables (2019 - 2021)

Vivos Therapeutics (VVOS) has 3 years of Loans and Notes Receivables data on file, last reported at $61864.0 in Q3 2021.

• Quarterly Loans and Notes Receivables changed N/A year-over-year to $61864.0 in Q3 2021, while the trailing twelve-month figure through Sep 2021 was $61864.0 (changed N/A YoY) and the FY2020 annual result came in at $84000.0, down 0.82% from the prior year.
• Loans and Notes Receivables advanced to $61864.0 in Q3 2021 per VVOS's latest filing, from $56732.0 in the prior quarter.
• Across five years, Loans and Notes Receivables topped out at $84696.0 in Q4 2019 and bottomed at $56732.0 in Q2 2021.
• The 3-year median for Loans and Notes Receivables is $84000.0 (2020), against an average of $74397.6.
• Peak annual rise in Loans and Notes Receivables reached 0.82% in 2020, while the deepest fall reached 0.82% in 2020.
• Tracing VVOS's Loans and Notes Receivables over 3 years: stood at $84696.0 in 2019, then decreased by 0.82% to $84000.0 in 2020, then fell by 26.35% to $61864.0 in 2021.
• Per Business Quant, the three latest VVOS Loans and Notes Receivables figures stand at $61864.0 (Q3 2021), $56732.0 (Q2 2021), and $84696.0 (Q1 2021).

Peer Comparison